Gavin Bahadur, Director of the Cataract Division of the Sinskey Eye Institute in Santa Monica, California will perform the first laser cataract removal
surgeries in the Western United States.
In practice, the consistently low temperatures during phacoemulsification, or cataract removal
, have been shown to minimize tissue damage and speed recovery from cataract surgery.
for the development of CT-3 for the treatment of pain, and with Bausch & Lomb for the Avantix cataract removal
performed the first laser cataract removal
in New Jersey at the Springfield Eye Surgery and Laser Center, patients are now inquiring about the procedure in ever increasing numbers.
It is by far the most efficient and flexible system ever developed for cataract removal
," said Richard Mackool, MD, Director of The Mackool Eye Institute and Laser Center and Senior Attending Surgeon at The New York Eye and Ear Infirmary.
In her cataract special, Roberts takes viewers into the operating room for a dramatic close-up look at her cataract removal
Atlantic currently has ownership interest in Avantix (formerly known as "Catarex"), a surgical device for cataract removal
being under development by Bausch and Lomb, IP 751 (formerly known as "CT-3"), a synthetic cannabinoid derivative for treating pain and inflammation under development by Indevus Pharmaceuticals, and ATV-02, a potent and broad-spectrum antimicrobial agent for the local treatment of topical infections.
Motter stated that with the acquisition of the Humphrey Line of Ultrasonic Diagnostic Products recently put into production at its facility in Salt Lake, its acquisition of the Mentor Ophthalmic Surgical Products division, its anticipated approval of its revolutionary Laser Cataract Removal
System currently completing successful clinical trials and its expanding opportunities with strategic alliance partner, Pharmacia & Upjohn, it is time to go to the next level in the investment banking community.
Nasdaq: PMED) announced today that it will acquire the assets of Mentor's Ophthalmics Phaco Cataract Removal
Division in a stock swap transaction valued at $1.
Nasdaq: PMED) announced today that it has submitted its "notice of intent to market" along with results from recent clinical trials of its patented probe and revolutionary laser cataract removal
system (the "Photon") to FDA for final approval.
These are namely the Avantix (formerly known as "Catarex"), a surgical device for cataract removal
being under development by Bausch and Lomb, and IP 751 (formerly known as "CT-3"), a synthetic cannabinoid derivative for treating pain and inflammation under development by Indevus Pharmaceuticals.
procedures for cataract removal
and pre-screening of